- Home
- PCVX
PCVX
Vaxcyte Inc.
as of 02-04-2026 1:51pm EST
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 6.1B | IPO Year: | 2020 |
| Target Price: | $97.67 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.66 - $91.77 | Next Earning Date: | 02-24-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vaxcyte Inc. (PCVX)
SVP, FINANCE
Avg Cost/Share
$47.92
Shares
11,623
Total Value
$556,971.85
Owned After
21,250
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cowan Elvia | PCVX | SVP, FINANCE | Dec 23, 2025 | Sell | $47.92 | 11,623 | $556,971.85 | 21,250 |
Compare PCVX vs Leading Stocks
See how PCVX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PCVX Vaxcyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.